Business context and reporting period
The supplied filing is Trovagene, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2016—not a filing identified as Cardiff Oncology, Inc. Investors should verify the issuer and filing match their intended company. Trovagene described itself as a molecular diagnostics company developing and commercializing urine- and blood-based cell-free DNA tests, including its Precision Cancer Monitoring platform.
Financial performance and liquidity
| Metric | Q3 2016 / Sep. 30, 2016 | Comparison |
|---|---|---|
| Revenue | $89,114 | $57,327 in Q3 2015 |
| Net loss attributable to common stockholders | $10.20 million | $2.74 million in Q3 2015 |
| Basic loss per share | $0.34 | $0.10 in Q3 2015 |
| Cash and cash equivalents | $22.57 million | $67.49 million at Dec. 31, 2015 |
| Short-term investments | $24.38 million | None reported at Dec. 31, 2015 |
| Working capital | $41.41 million | $60.18 million at Dec. 31, 2015 |
| Total liabilities | $26.23 million | $22.74 million at Dec. 31, 2015 |
For the nine months ended September 30, revenue was $313,000 versus $233,643 in 2015; net loss attributable to common stockholders was $30.67 million versus $20.11 million, and basic loss per share was $1.02 versus $0.80. Revenue remained very small relative to costs. The company reported negative gross margins while building test volume and addressing capacity inefficiencies.
Nine-month operating cash use was $22.03 million, compared with $15.31 million in 2015. Investing cash use was $25.25 million, largely due to net purchases of short-term investments; financing provided $2.36 million. At September 30, recorded current and long-term debt totaled approximately $16.40 million. The company reported $44.4 million of cash, cash equivalents and short-term investments at October 31, 2016.
Material changes versus prior periods
- Nine-month operating expenses rose to $30.68 million from $18.12 million, driven by higher research and development, selling and marketing, and general and administrative spending.
- Nine-month revenue increased by $79,357: diagnostic-service and clinical-research revenue grew, while royalties declined by $15,062.
- Q3 loss widened substantially. Operating expenses increased, and the warrant fair-value gain was much smaller than in Q3 2015; these noncash fair-value changes affected reported net loss.
- Cash and cash equivalents fell from year-end, while the company moved $24.45 million net into short-term investments.
Outlook, risks, and unusual items
- Management stated that additional capital would be required in 2017 to develop and commercialize product candidates and fund operations at projected spending levels. It warned financing may not be available on acceptable terms and could dilute shareholders or require business cutbacks, earlier collaborations, or disposition of technology rights.
- The company expected ongoing operating cash outflows for several years, and research and development spending could increase with additional studies, collaborations, and product development. Diagnostic revenue recognition depended on cash collections, making timing uncertain.
- Debt terms include floating-rate equipment borrowing, covenant requirements, and a $1.125 million final payment on the term loan; the company reported covenant compliance at September 30, 2016.
- Two lawsuits were in discovery: Trovagene’s claims against former executives concerning an alleged corporate opportunity, and Pathway Genomics’ claims against the company and its CEO. The company said it would defend the latter. Legal fees also contributed to higher G&A expense.
- Unusual items include $1.2 million of expense for a former CEO’s fully vested option grant, substantial stock-based compensation, and a related-party law firm engagement that incurred approximately $376,000 in fees through September 30.
- Management said disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter. It reported no material changes to previously disclosed risk factors.
Key facts for investors to verify
- Confirm whether Trovagene, Inc. and the September 30, 2016 reporting period are the intended issuer and period, given the Cardiff Oncology metadata.
- Assess cash runway against the stated need to raise capital in 2017, including subsequent financing and spending developments.
- Review test volumes, reimbursement collections, gross margins, and progress toward commercial scale, since revenue was minimal and costs exceeded revenue.
- Review debt maturities, final-payment obligations, interest-rate exposure, and covenant status.
- Track outcomes and potential costs of the disclosed litigation and review the related-party legal engagement.